HINGHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) introduced a big improvement milestone because it accomplished the GLP animal research for the LIBERTY® Robotic System, the primary disposable robotic system being developed for endovascular procedures. The research was carried out by a crew of seasoned Key Opinion Leaders (KOLs) within the endovascular area at a world-class MedTech analysis laboratory with FDA-required ranges of planning, controlling, monitoring, and reporting (GLP requirements), utilizing porcine mannequin.
In the course of the GLP animal research, the physicians carried out pre-determined 63 navigations to the focused websites utilizing the investigational LIBERTY Robotic System and carried out an equal variety of procedures manually. The efficiency endpoint of the LIBERTY Robotic System after robotic navigation was efficiently accomplished for 58 out of the 63 targets (92%), whereas 3 of the targets (4.8%) weren’t accomplished resulting from technical points and a pair of (3.2%) weren’t accomplished resulting from fluoroscopy associated points (non-device associated). Publish navigation intra-operative selective angiograms of the goal vessels confirmed no particular proof of acute vascular damage. Observe up angiograms of those vessels in post-procedure day 3 confirmed regular vessel anatomy with out indicators of damage. Preliminary postmortem gross pathology examination of among the goal organs confirmed preliminary findings, which shall be additional investigated within the pending histopathology evaluation, and doubtlessly an extra pre-clinical research.
Along with the target measurements, the efficiency and value of the LIBERTY Robotic System have been subjectively graded by every of the physicians, with their assessments accounting for options akin to ease of navigation to the goal, studying curve, and system stability. For the goal websites reached, the physicians graded the LIBERTY Robotic system on the highest grade.
“It was a really satisfying expertise,” commented Dr. Sebastian Flacke, MD PhD, Professor of Radiology Tufts Medical Faculty, Chief Interventional Radiology, Vice Chair for Analysis, Lahey Hospital and Medical Middle. “It provides you a really exact feeling on what you’re doing with quite a lot of management.”
“Set-up time is fast,” added Dr. Dmitry J. Rabkin, MD, Ph.D., FSIR, Assistant Chief, Division of Angiography and Interventional Radiology, Division of Radiology, Brigham and Ladies’s Hospital, after his personal expertise with LIBERTY throughout the GLP research. “The educational curve seems to be straightforward. The all-around expertise was excellent, delicate and exact.”
“We’re very proud and excited of how LIBERTY carried out throughout the GLP animal research,” commented Dr. Eyal Morag, Chief Medical Officer of Microbot. “It was thrilling to observe my very esteemed colleagues rapidly adapt to performing the procedures robotically, and their success in hitting the targets is a testomony to simply how accessible LIBERTY is.”
The LIBERTY Robotic System is investigational and has not been cleared by the U.S. Meals and Drug Administration for any use, and accordingly it isn’t commercially out there in the US or in some other market. The Firm plans to additional assist this research with further pre-clinical and scientific information.
About Microbot Medical Inc.
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical machine firm that focuses on transformational micro-robotic applied sciences, targeted totally on each pure and synthetic lumens inside the human physique. Microbot’s present proprietary technological platforms present the inspiration for the event of a Multi Technology Pipeline Portfolio (MGPP).
Microbot Medical was based in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the targets of bettering scientific outcomes for sufferers and rising accessibility by the usage of micro-robotic applied sciences. Additional details about Microbot Medical is accessible at http://www.microbotmedical.com.
Statements as to future monetary and/or working outcomes, future progress in analysis, know-how, scientific improvement, and potential alternatives for Microbot Medical Inc. and its subsidiaries, together with different statements concerning the future expectations, beliefs, targets, plans, or prospects expressed by administration, represent forward-looking statements inside the that means of the Non-public Securities Litigation Reform Act of 1995 and the Federal securities legal guidelines. Any statements that aren’t historic reality (together with, however not restricted to statements that include phrases akin to “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) must also be thought of to be forward-looking statements. Ahead-looking statements contain dangers and uncertainties, together with, with out limitation, market situations, dangers inherent within the improvement and/or commercialization of potential merchandise, together with LIBERTY, the result of its research to judge LIBERTY and different current and future applied sciences, uncertainty within the outcomes of pre-clinical research and scientific trials or regulatory pathways and regulatory approvals, uncertainty ensuing from the COVID-19 pandemic, want and talent to acquire future capital, and upkeep of mental property rights. Extra data on dangers going through Microbot Medical will be discovered underneath the heading “Danger Elements” in Microbot Medical’s periodic reviews filed with the Securities and Alternate Fee (SEC), which can be found on the SEC’s site at www.sec.gov. Microbot Medical disclaims any intent or obligation to replace these forward-looking statements, besides as required by regulation.